Capivasertib - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for capivasertib and what is the scope of freedom to operate?
Capivasertib
is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Capivasertib has ninety-three patent family members in forty-eight countries.
One supplier is listed for this compound.
Summary for capivasertib
| International Patents: | 93 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 31 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for capivasertib |
| What excipients (inactive ingredients) are in capivasertib? | capivasertib excipients list |
| DailyMed Link: | capivasertib at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for capivasertib
Generic Entry Date for capivasertib*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for capivasertib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Princess Maxima Center for Pediatric Oncology | PHASE1 |
| AbbVie | PHASE1 |
| Relay Therapeutics, Inc. | PHASE3 |
Anatomical Therapeutic Chemical (ATC) Classes for capivasertib
US Patents and Regulatory Information for capivasertib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | RX | Yes | No | 8,809,336 | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | 10,654,855 | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | RX | Yes | No | 11,760,760 | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | 9,006,430 | ⤷ Get Started Free | Y | ⤷ Get Started Free | |||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | 8,101,623 | ⤷ Get Started Free | Y | Y | ⤷ Get Started Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for capivasertib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | 9,006,430 | ⤷ Get Started Free |
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | 8,809,336 | ⤷ Get Started Free |
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | 9,006,430 | ⤷ Get Started Free |
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | 8,809,336 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for capivasertib
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ukraine | 100390 | ⤷ Get Started Free | |
| Israel | 204721 | ⤷ Get Started Free | |
| European Patent Office | 2201012 | DÉRIVÉS PYRROLO [2,3-D] PYRIMIDINE COMME INHIBITEURS DE LA PROTÉINE KINASE B (PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS) | ⤷ Get Started Free |
| Cuba | 20100062 | DERIVADOS DE PIRROLO [2,3-D] PIRIMIDINA COMO INHIBIDORES DE PROTEÍNAS QUINASAS B | ⤷ Get Started Free |
| Saudi Arabia | 08290625 | ⤷ Get Started Free | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for capivasertib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2201012 | CA 2024 00047 | Denmark | ⤷ Get Started Free | PRODUCT NAME: CAPIVASERTIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1820 20240618 |
| 2201012 | C202430046 | Spain | ⤷ Get Started Free | PRODUCT NAME: CAPIVASERTIB, OPCIONALMENTE EN FORMA DE UNA SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/24/1820; DATE OF AUTHORISATION: 20240617; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1820; DATE OF FIRST AUTHORISATION IN EEA: 20240617 |
| 2201012 | C02201012/01 | Switzerland | ⤷ Get Started Free | PRODUCT NAME: CAPIVASERTIBUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69300 19.03.2024 |
| 2201012 | 24C1046 | France | ⤷ Get Started Free | PRODUCT NAME: CAPIVASERTIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/24/1820 20240618 |
| 2201012 | 38/2024 | Austria | ⤷ Get Started Free | PRODUCT NAME: CAPIVASERTIB, WAHLWEISE IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/24/1820 (MITTEILUNG) 20240618 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Capivasertib
More… ↓
